GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sumitomo Pharma Co Ltd (OTCPK:DNPUF) » Definitions » 3-Year EBITDA Growth Rate

Sumitomo Pharma Co (Sumitomo Pharma Co) 3-Year EBITDA Growth Rate

: 0.00% (As of Dec. 2023)
View and export this data going back to 2009. Start your Free Trial

Sumitomo Pharma Co's EBITDA per Share for the three months ended in Dec. 2023 was $-0.38.

During the past 12 months, Sumitomo Pharma Co's average EBITDA Per Share Growth Rate was -203.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Sumitomo Pharma Co was 24.30% per year. The lowest was -4.40% per year. And the median was 3.80% per year.

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sumitomo Pharma Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sumitomo Pharma Co 3-Year EBITDA Growth Rate Distribution

For the Drug Manufacturers industry and Healthcare sector, Sumitomo Pharma Co's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Sumitomo Pharma Co's 3-Year EBITDA Growth Rate falls into.


Sumitomo Pharma Co 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Sumitomo Pharma Co  (OTCPK:DNPUF) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Sumitomo Pharma Co 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Sumitomo Pharma Co's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Sumitomo Pharma Co (Sumitomo Pharma Co) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sumitomo Pharma Co Ltd (OTCPK:DNPUF) » Definitions » 3-Year EBITDA Growth Rate
Comparable Companies
TSE:4540 TSE:4887 TSE:4547 TSE:4521 TSE:4534 TSE:4553 TSE:4569 TSE:4551 TSE:4559 TSE:4886 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 XSWX:SDZ VTRS NBIX
Traded in Other Exchanges
4506:Japan DPM:Germany
Address
6-8, Doshomachi 2-chome, Chuo-ku, Osaka, JPN, 541-0045
Website
https://www.sumitomo-pharma.com
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.